Abstract: Disclosed are strains of actinomycetes that produce manzamines or derivatives thereof, methods of isolating said strains, and a 16S rRNA useful in identifying manzamine-producing bacteria.

Abstract: We have now discovered that certain 9,10-anthraquinone derivatives we developed possess potent activity against O. perornata while possessing a sufficiently high level of solubility in water to make their activity against O. perornata viable. These compounds possess a high level of activity against O. perornata yet are relatively non-toxic to green algae and fishes. The compounds also possess a relatively short half-life. The compounds represent a new means to providing compounds possessing a high degree of selective activity against blue-green algae while being physiologically tolerated by catfish and green algae. The compounds provide a means for controlling blue-green algae in managed bodies of water that are destined for public use or consumption.

Abstract: A method of treating an infectious disease or condition in a subject in need of such treatment is disclosed. The method comprises administering to a subject an effective amount of a manzamine, manzamine derivative or analog or an optical isomer or racemate or tautomer thereof or a pharmaceutically acceptable salt thereof.

Abstract: A genomic DNA encoding a human imidazoline receptor is described. cDNAs encoding the receptor and fragments thereof are also provided. An amino acid sequence predicted to be 120,000 MW for nearly the entire protein is identified, as well as a middle fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Methods of preparing antibodies against the transfected protein are also described. Also, a screening method for identifying additional subtypes of this receptor are identified. Also, screening methods for identifying drugs that interact with the imidazoline receptor are described.

Abstract: A genomic DNA encoding a human imidazoline receptor is described. cDNAs encoding the receptor and fragments thereof are also provided. An amino acid sequence predicted to be 120,000 MW for nearly the entire protein is identified, as well as a middle fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Methods of preparing antibodies against the transfected protein are also described. Also, a screening method for identifying additional subtypes of this receptor are identified. Also, screening methods for identifying drugs that interact with the imidazoline receptor are described.

Abstract: It has been found that sampangine and related analogs such as benzo[4,5]sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant compositions and methods of using the materials for such a purpose are also provided.

Abstract: This invention comprises compositions containing dihydroartemisinin and dihydroartemisitene dimers with activity as anticancer agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor agents, one that has shown promising activity against solid tumors, and with a pattern of selectivity that suggests a possible new mechanism of action.

Abstract: A method for the isolation of delta-9-tetrahydrocannibinol (THC) from, Cannabis plant material, wherein delta-9-THC Acid and THC are separately obtained including the steps of extracting the Cannabis plant material, chelating delta-9-THC acid on alumina solid support from cannabis extracts rich in the acid washing of non-acid components of the extract with organic solvents and eluting of the delta-9-THC acid with strong polar solvents.

Abstract: A thermoacoustic refrigeration device employs a gas-vapor mixture as the working fluid. As a result, the refrigeration device operates according to a modified thermoacoustic refrigeration cycle that adds a condensation-vaporization cycle to the thermoacoustic cycle. The resulting modified refrigeration cycle increases the efficiency of heat transport by harnessing the translational motion of the vapor, as well as the usual acoustic oscillations, to transport the heat energy from one end of a thermal stack to the other.

Abstract: A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.

Abstract: A cDNA encoding a human imidazoline receptor is described. The amino acid sequence of the entire imidazoline receptor protein is identified, as well as a C-terminal fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Also, a screening method for identifying drugs that interact with the imidazoline receptor is described.

Abstract: A genomic DNA encoding a human imidazoline receptor is described. cDNAs encoding the receptor and fragments thereof are also provided. An amino acid sequence predicted to be 120,000 MW for nearly the entire protein is identified, as well as a middle fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Methods of preparing antibodies against the transfected protein are also described. Also, a screening method for identifying additional subtypes of this receptor are identified. Also, screening methods for identifying drugs that interact with the imidazoline receptor are described.

Abstract: A cDNA encoding a human imidazoline receptor is described. The amino acid sequence of the entire imidazoline receptor protein is identified, as well as a C-terminal fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Also, a screening method for identifying drugs that interact with the imidazoline receptor is described.

Abstract: A thermoacoustic refrigeration device employs a gas-vapor mixture as the working fluid. As a result, the refrigeration device operates according to a modified thermoacoustic refrigeration cycle that adds a condensation-vaporization cycle to the thermoacoustic cycle. The resulting modified refrigeration cycle increases the efficiency of heat transport by harnessing the translational motion of the vapor, as well as the usual acoustic oscillations, to transport the heat energy from one end of a thermal stack to the other.

Abstract: An embodiment of the present invention described and shown in the specification and drawings is a double lumen breathing tube for ventilating at least one lung of a subject. The distal ends of the tubes are predisposed to be spaced-apart and when in position in the airway of a human subject, each tube fits into a mainstem bronchus. A structure for temporarily positioning the distal ends of the tubes into a contacting or closely adjacent position is provided to facilitate introducing the breathing tube into the airway and for removing the breathing tube from the airway. Moreover, a method of ventilating at least one lung of a human subject is provided. This abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to ascertain quickly the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 C.F.R. §1.72(b).

Abstract: The present invention provides methods for stabilizing proteins, preventing protein aggregation, renaturation of previously-denatured proteins, reactivating a protein that has been inactivated by denaturation, preserving enzyme activities under conditions of elevated temperatures, inducing thermotolerance in bacteria, increasing the temperature optimum for the activity of an enzyme, and preventing formation of inclusion bodies by bacterially-expressed recombinant proteins.

Abstract: It has been found that one of the enantiomers of 8-aminoquinoline antiparasitic compounds is surprisingly more active than the other enantiomer against parasitic infections including opportunistic parasitic infections. These enantiomers as well as pharmaceutical compositions containing pure enantiomers are disclosed. Also disclosed is a novel class of 8-aminoquinolines which contain a tri-substituted phenoxy substitution.

Abstract: A method of preparing THC using extraction of plant material with a non-polar solvent followed by vacuum distillation and chromatography.

Abstract: The present invention provides methods for stabilizing proteins, preventing protein aggregation, renaturation of previously-denatured proteins, reactivating a protein that has been inactivated by denaturation, preserving enzyme activities under conditions of elevated temperatures, inducing thermotolerance in bacteria, increasing the temperature optimum for the activity of an enzyme, and preventing formation of inclusion bodies by bacterially-expressed recombinant proteins.

Abstract: This invention provides new thiazolindinedione derivatives and new arylacetic acid derivatives. These compounds are useful for the treatment of cardiovascular diseases, certain endocrine diseases, certain inflammatory diseases, certain neoplastic (malignant) and non-malignant proliferative diseases, certain neuro-psychiatric disorders, certain viral diseases, and diseases associated with these viral infections as discussed herein.